FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1623479996> ?p ?o ?g. }

• W1623479996 endingPage "1100" @default.
• W1623479996 startingPage "1093" @default.
• W1623479996 abstract "Evaluate the efficacy and toxicity of image guided brachytherapy using inverse planning simulated annealing (IPSA) high-dose-rate brachytherapy (HDRB) boost for locoregionally advanced cervical cancer.From December 2003 through September 2009, 111 patients with primary cervical cancer were treated definitively with IPSA-planned HDRB boost (28 Gy in 4 fractions) after external radiation at our institution. We performed a retrospective review of our experience using image guided brachytherapy. Of the patients, 70% had a tumor size >4 cm, 38% had regional nodal disease, and 15% had clinically evident distant metastasis, including nonregional nodal disease, at the time of diagnosis. Surgical staging involving pelvic lymph node dissection was performed in 15% of patients, and 93% received concurrent cisplatin-based chemotherapy. Toxicities are reported according to the Common Terminology Criteria for Adverse Events version 4.0 guidelines.With a median follow-up time of 42 months (range, 3-84 months), no acute or late toxicities of grade 4 or higher were observed, and grade 3 toxicities (both acute and late) developed in 8 patients (1 constitutional, 1 hematologic, 2 genitourinary, 4 gastrointestinal). The 4-year Kaplan-Meier estimate of late grade 3 toxicity was 8%. Local recurrence developed in 5 patients (4 to 9 months after HDRB), regional recurrence in 3 (6, 16, and 72 months after HDRB), and locoregional recurrence in 1 (4 months after HDR boost). The 4-year estimates of local, locoregional, and distant control of disease were 94.0%, 91.9%, and 69.1%, respectively. The overall and disease-free survival rates at 4 years were 64.3% (95% confidence interval [CI] of 54%-73%) and 61.0% (95% CI, 51%-70%), respectively.Definitive radiation by use of inverse planned HDRB boost for locoregionally advanced cervical cancer is well tolerated and achieves excellent local control of disease. However, overall survival continues to be limited by the high rates of distant metastasis." @default.
• W1623479996 created "2016-06-24" @default.
• W1623479996 creator A5002391153 @default.
• W1623479996 creator A5024129361 @default.
• W1623479996 creator A5029863208 @default.
• W1623479996 creator A5039728792 @default.
• W1623479996 creator A5040458861 @default.
• W1623479996 creator A5042728664 @default.
• W1623479996 creator A5055171297 @default.
• W1623479996 creator A5086278071 @default.
• W1623479996 date "2015-08-01" @default.
• W1623479996 modified "2023-10-07" @default.
• W1623479996 title "Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes" @default.
• W1623479996 cites W1585451102 @default.
• W1623479996 cites W1935824237 @default.
• W1623479996 cites W1975364211 @default.
• W1623479996 cites W1977479761 @default.
• W1623479996 cites W1981542861 @default.
• W1623479996 cites W1981668173 @default.
• W1623479996 cites W1981680003 @default.
• W1623479996 cites W1985213644 @default.
• W1623479996 cites W1996583541 @default.
• W1623479996 cites W1998677251 @default.
• W1623479996 cites W1999724502 @default.
• W1623479996 cites W2018540825 @default.
• W1623479996 cites W2024060531 @default.
• W1623479996 cites W2025526775 @default.
• W1623479996 cites W2030607437 @default.
• W1623479996 cites W2037063870 @default.
• W1623479996 cites W2042026763 @default.
• W1623479996 cites W2042262831 @default.
• W1623479996 cites W2046331035 @default.
• W1623479996 cites W2052636266 @default.
• W1623479996 cites W2054407424 @default.
• W1623479996 cites W2064617342 @default.
• W1623479996 cites W2065574271 @default.
• W1623479996 cites W2078308579 @default.
• W1623479996 cites W2081977840 @default.
• W1623479996 cites W2086333899 @default.
• W1623479996 cites W2091172221 @default.
• W1623479996 cites W2097945491 @default.
• W1623479996 cites W2098095195 @default.
• W1623479996 cites W2104360894 @default.
• W1623479996 cites W2115146864 @default.
• W1623479996 cites W2122321342 @default.
• W1623479996 cites W2131420706 @default.
• W1623479996 cites W2131860931 @default.
• W1623479996 cites W2137751332 @default.
• W1623479996 cites W2153639787 @default.
• W1623479996 cites W2156281133 @default.
• W1623479996 cites W2157719711 @default.
• W1623479996 cites W2158690105 @default.
• W1623479996 cites W2161812609 @default.
• W1623479996 cites W2167486697 @default.
• W1623479996 cites W2324392028 @default.
• W1623479996 cites W2328935341 @default.
• W1623479996 cites W2480089904 @default.
• W1623479996 doi "https://doi.org/10.1016/j.ijrobp.2015.04.018" @default.
• W1623479996 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26194683" @default.
• W1623479996 hasPublicationYear "2015" @default.
• W1623479996 type Work @default.
• W1623479996 sameAs 1623479996 @default.
• W1623479996 citedByCount "31" @default.
• W1623479996 countsByYear W16234799962015 @default.
• W1623479996 countsByYear W16234799962016 @default.
• W1623479996 countsByYear W16234799962017 @default.
• W1623479996 countsByYear W16234799962018 @default.
• W1623479996 countsByYear W16234799962019 @default.
• W1623479996 countsByYear W16234799962020 @default.
• W1623479996 countsByYear W16234799962021 @default.
• W1623479996 countsByYear W16234799962022 @default.
• W1623479996 countsByYear W16234799962023 @default.
• W1623479996 crossrefType "journal-article" @default.
• W1623479996 hasAuthorship W1623479996A5002391153 @default.
• W1623479996 hasAuthorship W1623479996A5024129361 @default.
• W1623479996 hasAuthorship W1623479996A5029863208 @default.
• W1623479996 hasAuthorship W1623479996A5039728792 @default.
• W1623479996 hasAuthorship W1623479996A5040458861 @default.
• W1623479996 hasAuthorship W1623479996A5042728664 @default.
• W1623479996 hasAuthorship W1623479996A5055171297 @default.
• W1623479996 hasAuthorship W1623479996A5086278071 @default.
• W1623479996 hasConcept C121608353 @default.
• W1623479996 hasConcept C126322002 @default.
• W1623479996 hasConcept C126838900 @default.
• W1623479996 hasConcept C133507102 @default.
• W1623479996 hasConcept C141071460 @default.
• W1623479996 hasConcept C2777088508 @default.
• W1623479996 hasConcept C2777416452 @default.
• W1623479996 hasConcept C2777793932 @default.
• W1623479996 hasConcept C2778220009 @default.
• W1623479996 hasConcept C509974204 @default.
• W1623479996 hasConcept C71924100 @default.
• W1623479996 hasConceptScore W1623479996C121608353 @default.
• W1623479996 hasConceptScore W1623479996C126322002 @default.
• W1623479996 hasConceptScore W1623479996C126838900 @default.
• W1623479996 hasConceptScore W1623479996C133507102 @default.
• W1623479996 hasConceptScore W1623479996C141071460 @default.
• W1623479996 hasConceptScore W1623479996C2777088508 @default.

• next